R&D News | pharmaphorum

News

Novartis lines up Merck exec to replace R&D leader Jay Bradn...

Jay Bradner, president of the Novartis Institutes for Biomedical Research (NIBR), is retiring from the position after seven years in the role, and will be replaced by Merck & Co R&D

News

AZ blocks former exec from taking up role at GSK – for now

AstraZeneca has succeeded in a last-gasp effort to stop its former head of investor relations joining rival UK pharma group GSK, after winning an injunction in the High Court in London.

News

Jounce setback casts deeper pall over ICOS as cancer target

A phase 2 trial of Jounce Therapeutics' ICOS agonist vopratelimab has ended in failure, casting further doubt about the validity of ICOS as a target for cancer therapies.

News

Futura eyes FDA filing as topical ED drug passes phase 3 tes...

Futura Medical's development of a topical treatment for erectile dysfunction (ED) is approaching the finish line in the US, as the UK biotech reports confirmatory phase 3 data ahead of an F

News

Phase 3 trial confirms Lumakras role in lung cancer

Amgen's pathfinder KRAS inhibitor Lumakras has been shown to be effective in KRAS-mutated non-small cell lung cancer (NSCLC) in a phase 3 trial that should serve as a confirmation study for

News

ESC22: AstraZeneca's Farxiga DELIVERs in heart failure

AstraZeneca's Farxiga reduced the risk of hospitalisation and death in people with all types of heart failure in the DELIVER trial, which could dramatically increase the population of patie

Novartis lines up Merck exec to replace R&D leader Jay Bradn...

AZ blocks former exec from taking up role at GSK – for now

Jounce setback casts deeper pall over ICOS as cancer target

Futura eyes FDA filing as topical ED drug passes phase 3 tes...

Phase 3 trial confirms Lumakras role in lung cancer

ESC22: AstraZeneca's Farxiga DELIVERs in heart failure

Moderna's Q1 revenues rocket, thanks to ex-US sales

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks